Univest
Univest
  • Markets

Sun Pharma vs Dr Reddy’s 2027: Profits Fell Over 30% at Both, Yet One Stock Sits Near Its 52-Week High

  • November 20, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Sun Pharma vs Dr Reddy's 2027: Profits Fell Over 30% at Both, Yet One Stock Sits Near Its 52-Week High
Sun Pharma vs Dr Reddy's at a glance Sun Pharmaceutical Industries Dr. Reddy's Laboratories
Share price (19 Nov 2026) Rs 1,900.00 Rs 1,400.90
Market cap Rs 4,56,593 crore Rs 1,16,771 crore
P/E ratio 41.56 42.31
Q2 FY27 net profit Rs 2,002 crore Rs 913.2 crore

Quick Answer

Sun Pharma vs Dr Reddy's compares India’s largest drugmaker with one of its most global generic companies after a weak quarter for both. In Q2 FY27, Sun Pharma’s revenue rose 11.8% to Rs 16,716 crore but net profit fell 36.2% to Rs 2,002 crore. Dr Reddy’s revenue slipped 3.3% to Rs 8,854 crore and net profit fell 31.7% to Rs 913 crore. Both trade at a P/E near 42, but Sun Pharma’s ROE of 13.79% is almost twice Dr Reddy’s 7.21%.

Sun Pharma vs Dr Reddy's in 2027 looks unusual on the numbers: both companies reported a September quarter profit fall of more than 30%, yet Dr Reddy’s share price sits within 1% of its 52-week high and Sun Pharma is about 7% below its own. The Sun Pharma vs Dr Reddy's Q2 results show why the market reads each fall differently.

Both are Nifty 50 pharma heavyweights. Sun Pharmaceutical Industries is valued at about Rs 4,56,593 crore and Dr. Reddy’s Laboratories at about Rs 1,16,771 crore. This Sun Pharma vs Dr Reddy's guide compares their business mix, valuation, Q2 FY27 results, outlook, risks and shareholding.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Sun Pharma vs Dr Reddy’s: Company Overview
    • What Sun Pharmaceutical Industries Does
    • What Dr. Reddy's Laboratories Does
  • How Sun Pharma and Dr Reddy’s Make Money
  • Sun Pharma vs Dr Reddy’s Valuation and Key Metrics
  • Sun Pharma vs Dr Reddy’s Q2 FY27 Results
  • Sun Pharma vs Dr Reddy’s Outlook After the Q2 Results
    • Sun Pharma: specialty growth and margins
    • Dr Reddy’s: rebuilding after a product cycle
  • Risks in Sun Pharma vs Dr Reddy’s
    • Risks for Sun Pharmaceutical Industries
    • Risks for Dr. Reddy's Laboratories
  • Sun Pharma vs Dr Reddy’s Shareholding
  • Which Investor Does Each Pharma Stock Suit?
    • Sun Pharma suits investors who want specialty-led growth
    • Dr Reddy’s suits investors betting on a launch-led recovery
  • Final View on Sun Pharma vs Dr Reddy’s
  • FAQs on Sun Pharma vs Dr Reddy’s
    • Why did Sun Pharma's profit fall in Q2 FY27?
    • Why is Dr Reddy's stock near its 52-week high after weak results?
    • Which pharma stock has the higher ROE?
    • What is the P/E of Sun Pharma and Dr Reddy's?
    • How big are Sun Pharma and Dr Reddy's?
    • Who owns Sun Pharma and Dr Reddy's?
    • Is Sun Pharma vs Dr Reddy's a buy or sell decision?

Sun Pharma vs Dr Reddy’s: Company Overview

What Sun Pharmaceutical Industries Does

Sun Pharmaceutical Industries is India’s largest pharmaceutical company and a leading generic and specialty drugmaker in the US. Its specialty portfolio, led by dermatology and other branded products, has become a large share of its global earnings. Promoters hold 52.68%.

What Dr. Reddy's Laboratories Does

Dr. Reddy’s Laboratories, based in Hyderabad, makes generic medicines, active pharmaceutical ingredients and branded drugs for India, the US, Russia and other markets. Its promoter group holds 26.63%, and institutions own most of the rest.

How Sun Pharma and Dr Reddy’s Make Money

Both earn from branded generics in India, generic drugs in the US and other export markets, and bulk drug sales. Profit depends heavily on the US, where a few high-value products can lift or cut margins sharply.

The key difference in Sun Pharma vs Dr Reddy's is mix. Sun Pharma earns a growing share from patented specialty brands, which carry steadier pricing. Dr Reddy’s relies more on generics, where prices fall once competition arrives, so its profit swings more with individual product cycles.

Sun Pharma vs Dr Reddy’s Valuation and Key Metrics

These figures use the 19 November 2026 close and trailing twelve month ratios.

Sun Pharma vs Dr Reddy's metric Sun Pharmaceutical Industries Dr. Reddy's Laboratories
Share price (CMP) Rs 1,900.00 Rs 1,400.90
52-week high Rs 2,046.90 Rs 1,414.90
52-week low Rs 1,583.70 Rs 1,101.00
Distance from 52-week high -7.2% -1.0%
Market capitalisation Rs 4,56,593 crore Rs 1,16,771 crore
P/E ratio (TTM) 41.56 42.31
Industry P/E 40.13 40.13
P/B ratio 5.11 3.01
Return on equity (ROE) 13.79% 7.21%
Debt to equity 0.04 0.19
Dividend yield 0.84% 0.57%
FY26 revenue Rs 61,674 crore Rs 35,059 crore
FY26 net profit Rs 11,565 crore Rs 4,158 crore

The Sun Pharma vs Dr Reddy's table shows near-identical earnings multiples, with Sun Pharma at a P/E of 41.56 and Dr Reddy’s at 42.31. The pharma industry P/E is 40.13, so both trade slightly above the sector.

Sun Pharma has the higher return on equity at 13.79% against 7.21%, and a higher P/B of 5.11 against 3.01. Both carry little debt.

Dr Reddy’s at Rs 1,400.90 is only about 1.0% below its 52-week high of Rs 1,414.90. Sun Pharma at Rs 1,900 is about 7.2% below its high of Rs 2,046.90.

Sun Pharma vs Dr Reddy’s Q2 FY27 Results

Figures below are consolidated revenue and net profit for the quarter ended 30 September 2026.

Sun Pharma vs Dr Reddy's Q2 FY27 (Sep 2026 quarter) Sun Pharmaceutical Industries Dr. Reddy's Laboratories
Revenue Q2 FY27 Rs 16,716 crore Rs 8,854 crore
Revenue Q2 FY26 Rs 14,948 crore Rs 9,152 crore
Revenue change YoY +11.8% -3.3%
Net profit Q2 FY27 Rs 2,002 crore Rs 913.2 crore
Net profit Q2 FY26 Rs 3,137 crore Rs 1,337 crore
Net profit change YoY -36.2% -31.7%
Net profit Q1 FY27 Rs 2,911 crore Rs 435.6 crore

In the Q2 FY27 results, Sun Pharma’s revenue rose 11.8% to Rs 16,716 crore, but net profit fell 36.2% to Rs 2,001.6 crore. Its operating margin dropped to 24.8% from 34.7%, and profit was also below the Rs 2,910.8 crore of the June quarter.

Dr Reddy’s revenue fell 3.3% to Rs 8,854 crore and net profit fell 31.7% to Rs 913.2 crore. However, profit more than doubled from Rs 435.6 crore in Q1 FY27, which helps explain why the stock has held near its high.

For Sun Pharma vs Dr Reddy's, Sun Pharma’s fall came alongside growing sales, while Dr Reddy’s showed a sharp sequential recovery from a weak June quarter.

Sun Pharma vs Dr Reddy’s Outlook After the Q2 Results

Sun Pharma: specialty growth and margins

Sun Pharma’s FY26 revenue rose 12.7% to Rs 61,674 crore and net profit 5.3% to Rs 11,565 crore. Its outlook depends on specialty brand growth in the US and steady growth in India.

The 10-point fall in operating margin in Q2 FY27 is the number investors will watch most closely in the coming quarters.

Dr Reddy’s: rebuilding after a product cycle

Dr Reddy’s FY26 net profit fell 27.4% to Rs 4,158 crore, as contributions from a large US generic product faded. Its recovery depends on new US launches, biosimilars and growth in India and emerging markets.

In the Sun Pharma vs Dr Reddy's Q2 results debate, the market appears to be valuing Dr Reddy’s on the sequential recovery rather than the year-on-year fall.

Compare pharma stocks on the Univest Screener

Risks in Sun Pharma vs Dr Reddy’s

Risks for Sun Pharmaceutical Industries

Sun Pharma’s main risk is that its margin does not recover from the Q2 FY27 drop. US regulatory action on plants and pricing pressure are ongoing risks. Promoters trimmed their stake from 54.48% to 52.68% and foreign institutions from 16.55% to 14.36%.

Risks for Dr. Reddy's Laboratories

In the Sun Pharma vs Dr Reddy's risk check, Dr Reddy’s faces generic price erosion and dependence on new launches. With its share price near the high and an ROE of 7.21%, expectations of a recovery are already priced in.

Sun Pharma vs Dr Reddy’s Shareholding

Sun Pharma vs Dr Reddy's shareholding (Sep ’26, change vs Sep ’25) Sun Pharmaceutical Industries Dr. Reddy's Laboratories
Promoters 52.68% (-1.80 pts) 26.63% (-0.01 pts)
Foreign institutions (FII) 14.36% (-2.19 pts) 31.39% (-4.13 pts)
Domestic institutions (DII) 22.27% (+2.04 pts) 31.88% (+3.90 pts)
Public and others 10.70% (+1.97 pts) 10.10% (+0.24 pts)

Sun Pharma promoters hold 52.68%. Domestic institutions raised their stake from 20.23% to 22.27%.

Dr Reddy’s promoters hold 26.63%. Domestic institutions raised their stake from 27.98% to 31.88%, while foreign institutions cut theirs from 35.52% to 31.39%. In Sun Pharma vs Dr Reddy's, domestic funds have been buying both stocks.

Download the Univest iOS App or Univest Android App to track Sun Pharma and Dr Reddy’s live and follow pharma sector research.

Which Investor Does Each Pharma Stock Suit?

Sun Pharma suits investors who want specialty-led growth

Within Sun Pharma vs Dr Reddy's, Sun Pharma fits investors who want the largest Indian drugmaker with a growing specialty business and higher ROE. They need to watch margins after the Q2 FY27 drop.

Dr Reddy’s suits investors betting on a launch-led recovery

Dr Reddy’s fits investors who expect new launches to rebuild profit after FY26. They need to accept a low ROE and a stock already near its high.

Final View on Sun Pharma vs Dr Reddy’s

Sun Pharma vs Dr Reddy's shows two different readings of a weak quarter. Sun Pharma grew sales 11.8% but saw profit fall 36.2% on lower margins. Dr Reddy’s profit fell 31.7% year on year but more than doubled from Q1 FY27, and its stock sits near its high.

Both trade at a P/E of about 42. The Sun Pharma vs Dr Reddy's outlook for 2027 depends on Sun Pharma’s margin recovery and Dr Reddy’s new launch pipeline.

Disclaimer: Data and figures in this article are drawn from publicly available information and company disclosures, and they may change after publication. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Sun Pharma vs Dr Reddy’s

Why did Sun Pharma's profit fall in Q2 FY27?

Ans. Sun Pharma's net profit fell 36.2% to Rs 2,001.6 crore in Q2 FY27, even though revenue rose 11.8% to Rs 16,716 crore. Its operating margin dropped to 24.8% from 34.7%. Higher costs and a changing product mix weighed on profit. Profit was also below the June quarter.

Why is Dr Reddy's stock near its 52-week high after weak results?

Ans. Dr Reddy's closed at Rs 1,400.90 on 19 November 2026, about 1% below its 52-week high of Rs 1,414.90. Its Q2 FY27 profit fell 31.7% year on year to Rs 913.2 crore. However, profit more than doubled from Rs 435.6 crore in the June quarter. Investors appear to be focusing on that recovery.

Which pharma stock has the higher ROE?

Ans. Sun Pharma has a return on equity of 13.79%, compared with 7.21% for Dr Reddy's. Sun Pharma's specialty brands support higher margins. Dr Reddy's ROE fell as FY26 profit dropped 27.4%. Both companies carry little debt.

What is the P/E of Sun Pharma and Dr Reddy's?

Ans. Sun Pharma trades at a P/E of 41.56 and Dr Reddy's at 42.31 as of 19 November 2026. The pharma industry P/E is 40.13. Both trade slightly above the sector. Their multiples are almost the same despite different profit trends.

How big are Sun Pharma and Dr Reddy's?

Ans. Sun Pharma has a market cap of about Rs 4,56,593 crore, nearly four times Dr Reddy's Rs 1,16,771 crore. Sun Pharma's FY26 revenue was Rs 61,674 crore against Rs 35,059 crore for Dr Reddy's. Sun Pharma's FY26 net profit was Rs 11,565 crore and Dr Reddy's was Rs 4,158 crore. Both are Nifty 50 companies.

Who owns Sun Pharma and Dr Reddy's?

Ans. Sun Pharma's promoters hold 52.68%, while Dr Reddy's promoters hold 26.63%. Domestic institutions hold 22.27% of Sun Pharma and 31.88% of Dr Reddy's. Foreign institutions hold 14.36% and 31.39% respectively. Domestic funds raised their stakes in both over the year.

Is Sun Pharma vs Dr Reddy's a buy or sell decision?

Ans. This Sun Pharma vs Dr Reddy's comparison is educational and does not give a buy or sell call. Sun Pharma offers scale and a specialty business with margin pressure, while Dr Reddy's offers a recovery case with a low ROE. Both trade near 42 times earnings. Investors should consult a SEBI-registered adviser before acting.



2027 Dr Reddy's Laboratories pharmaceuticals Stock Comparison Sun Pharmaceutical Industries
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply